---
document_datetime: 2023-09-21 19:48:39
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/xospata-epar-all-authorised-presentations_en.pdf
document_name: xospata-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.6214815
conversion_datetime: 2025-12-23 06:19:33.581358
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form   | Route of Administration   | Immediate Packaging                    | Pack size   |
|------------------|-------------------|------------|-----------------------|---------------------------|----------------------------------------|-------------|
| EU/1/19/1399/001 | XOSPATA           | 40 mg      | Film-coated tablet    | Oral use                  | blister (OPA/aluminium/PVC/ aluminium) | 84 tablets  |